Ponatinib is an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.
Ponatinib is a tyrosine kinase receptor inhibitor that is used in the therapy of refractory chronic myelogenous leukemia (CML) positive for the Philadelphia chromosome. Ponatinib is commonly associated with transient elevations in serum aminotransferase levels during treatment, but with only rare instances of clinically apparent acute liver injury.
Ponatinib is a benzamide obtained by the formal condensation of the carboxy group of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl benzoic acid with the aniline group of 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline. It is a multi-target tyrosine kinase inhibitor that targets ABL, SRC, FGFR, and others and was designed to overcome the resistance of BCR-ABL mutation to imatinib, in particular the gatekeeper mutation ABL(T315I). It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is an N-methyl piperazine, a member of benzamides, an acetylenic compound, an imidazopyridine, and a member of (trifluoromethyl)benzenes. It is a conjugate base of ponatinib(1+).
Ponatinib Hydrochloride is the hydrochloride salt form of an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.
Ponatinib hydrochloride is the hydrochloride salt of ponatinib. It is a potent pan inhibitor of tyrosine kinases, active in all single resistance ABL kinase mutations including the T315l mutation. It is approved for the treatment of chronic myeloid leukemia. It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It contains ponatinib(1+).
Mechanism of Action
Ponatinib is a multi-target kinase inhibitor. Its primary cellular target is the Bcr-Abl tyrosine kinase protein which is constitutively active and promotes the progression of CML. This protein arises from the fused Bcr and Abl genes- what is commonly known as the Philadelphia chromosome. Ponatinib is unique in that it is especially useful in the treatment of resistant CML because it inhibits the tyrosine kinase activity of Abl and T315I mutant kinases. The T315I mutation confers resistance in cells as it prevents other Bcr-Abl inhibitors from binding to the Abl kinase. Other targets that ponatinib inhibits are members of the VEGFR, PDGFR, FGFR, EPH receptors, and SRC families of kinases, and KIT, RET, TIE2, and FLT3. A decrease in tumor size expressing native or T315I mutant BCR-ABL has been observed in rats.
or
Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC50 concentrations of 0.4 and 2.0 nM, respectively. Ponatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors, and SRC families of kinases, and KIT, RET, TIE2, and FLT3. Ponatinib inhibited the in vitro viability of cells expressing native or mutant BCR-ABL, including T315I. In mice, treatment with ponatinib reduced the size of tumors expressing native or T315I mutant BCR-ABL when compared to controls.
Gain-of-function mutations of membrane receptor tyrosine kinase KIT especially gate-keeper D816V point mutation in KIT render kinase auto-activation, disease progression, and poor prognosis. D816V KIT is found in -80% of the patients of systemic mastocytosis (SM) and is resistant to the first and second generations of tyrosine kinase inhibitors (TKIs). The purpose of this investigation was aimed at explore whether ponatinib (AP24534), a novel effective TKI against T315I Bcr-Abl was active against D816V KIT. /The researchers/ discovered that ponatinib abrogated the phosphorylation of KIT harboring either V560G (sensitive to imatinib) or D816V mutation (resistant to imatinib) and the downstream signaling transduction. Ponatinib inhibited the growth of D816V KIT-expressing cells in culture and nude mouse xenografted tumors. Ponatinib triggered apoptosis by inducing the release of cytochrome c and AIF, downregulation of Mcl-1. Furthermore, ponatinib abrogated the phosphorylation of beta-catenin at site Y654, suppressed the translocation of beta-catenin, inhibited the transcription and DNA binding of TCF and the expression of its targets (e.g. Axin2, c-Myc, and cyclin D1). Moreover, ponatinib was highly active against xenografted D816V KIT tumors in nude mice and significantly prolonged the survival of mice with aggressive SM or mast cell leukemia by impeding the expansion and infiltration of mast cells with imatinib-resistant D814Y KIT.
Indications
- Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
- Iclusig is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
- Iclusig is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
- Treatment of acute lymphoblastic leukaemia, Treatment of chronic myeloid leukaemia
- Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia.
- Accelerated phase chronic myologenic leukemia
- Acute Lymphoblastic Leukemia (ALL)
- Myeloid Leukemia, Chronic, Chronic Phase
- Blast phase Chronic myelocytic leukemia
Contraindications
- anemia
- decreased blood platelets
- low levels of a type of white blood cell called neutrophils
- high blood pressure
- a heart attack
- acute blood clot in the heart
- coronary artery disease
- slow heartbeat
- supraventricular arrhythmias, a type of abnormal heart rhythm
- chronic heart failure
- sudden and serious symptoms of heart failure called acute decompensated heart failure
- a blood clot in the brain
- a stroke
- a localized weakening and ballooning in an artery wall called an arterial aneurysm
- obstruction of a blood vessel by a blood clot
- a blood clot in an artery
- peripheral vascular disease
- blood clot formation in vein
- bleeding
- blockage or closing off of blood vessels
- damage to the liver and inflammation
- recent operation
- visible water retention
- abnormal liver function tests
- impaired wound healing
- pregnancy
- a patient who is producing milk and breastfeeding
- a rupture in the wall of the stomach or intestine
- reactivation of hepatitis B infection
- pancreatitis
- a type of brain disorder called posterior reversible encephalopathy syndrome
- dissection of artery
Dosage
Strengths: 30 mg; 45 mg; 15 mg; 10 mg
Chronic Myelogenous Leukemia
Chronic phase chronic myeloid leukemia (CP-CML):
- Initial Dose: 45 mg orally once a day
- Upon achievement of 1% BCR-ABL1 or less (standardized according to International Scale): 15 mg orally once a day
- For loss of response: Re-escalate to a previously tolerated dosage of 30 mg or 45 mg orally once a day
Accelerated phase chronic myeloid leukemia (AP-CML), blast phase chronic myeloid leukemia (BP-CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL):
- Initial dose: 45 mg orally once a day
- The optimal dose has not been identified for AP-CML, BP-CML, and Ph+ ALL.
- Consider dose reduction for AP-CML patients who have achieved major cytogenic response.
- Continue treatment until loss of response or unacceptable toxicity.
- Drug discontinuation should be considered if patient response has not occurred by 3 months (90 days).
- This drug is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML).
- For the treatment of adult patients with CP-CML with resistance or intolerance to at least two prior kinase inhibitors
- For the treatment of adult patients with AP-CML, or BP-CML or Ph+ ALL for whom no other kinase inhibitors are indicated
- For the treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL
Acute Lymphoblastic Leukemia
Chronic phase chronic myeloid leukemia (CP-CML):
- Initial Dose: 45 mg orally once a day
- Upon achievement of 1% BCR-ABL1 or less (standardized according to International Scale): 15 mg orally once a day
- For loss of response: Re-escalate to a previously tolerated dosage of 30 mg or 45 mg orally once a day
Accelerated phase chronic myeloid leukemia (AP-CML), blast phase chronic myeloid leukemia (BP-CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL):
- Initial dose: 45 mg orally once a day
- The optimal dose has not been identified for AP-CML, BP-CML, and Ph+ ALL.
- Consider dose reduction for AP-CML patients who have achieved major cytogenic response.
- Continue treatment until loss of response or unacceptable toxicity.
- Drug discontinuation should be considered if patient response has not occurred by 3 months (90 days).
- This drug is not indicated and is not recommended for the treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML).
- For the treatment of adult patients with CP-CML with resistance or intolerance to at least two prior kinase inhibitors
- For the treatment of adult patients with AP-CML, or BP-CML or Ph+ ALL for whom no other kinase inhibitors are indicated
- For the treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Ph+ ALL
Liver Dose Adjustments
ANY LEVEL OF LIVER DYSFUNCTION (CHILD-PUGH A, B, OR C):
- Reduce the initial dose to 30 mg once a day in patients with preexisting liver dysfunction (Child-Pugh A, B, or C) and monitor for adverse reactions.
- The safety of multiple doses, or doses higher than 30 mg have not been studied in patients with hepatic impairment.
IF HEPATOTOXICITY DEVELOPS DURING TREATMENT:
Elevation of liver transaminase greater than 3 times the upper limit of normal (ULN) and if:
- Occurrence at 45 mg: Interrupt dosing and monitor hepatic function; and resume treatment at 30 mg after recovery to Grade 1 or less (less than 3 x ULN)
- AST or ALT at least 3 times ULN with an elevation of bilirubin greater than 2 times ULN and alkaline phosphatase less than 2 times ULN: Discontinue treatment
Dose Adjustments
- Patients with chronic phase myeloid leukemia who have achieved a 1% BCR-ABL1 or less (standardized according to International Scale) or patients with accelerated phase chronic myeloid leukemia who achieve a major cytogenetic response: Consider reducing the dose
- If response to treatment has not occurred by 3 months: Consider treatment discontinuation
DOSAGE MODIFICATION FOR COADMINISTRATION OF STRONG CYP450 3A INHIBITORS/INDUCERS:
- Concomitant use of strong CYP450 3A inducer: Avoid unless the benefit outweighs the risk and monitor for reduced efficacy; select a concomitant medication with no or minimal CYP450 3A induction potential if possible
- Concomitant use of strong CYP450 3A inhibitors:
- If current dose 45 mg once a day: Reduce dose to 30 mg once a day
- If current dose 30 mg once a day: Reduce dose to 15 mg once a day
- If current dose is 15 mg once a day: Reduce dose to 10 mg once a day
- If current dose is 10 mg once a day: Avoid use
- Resume the dosage that was tolerated prior to initiating the strong CYP450 3A inhibitor after the strong CYP450 3A inhibitor has been discontinued for 3 to 5 elimination half-lives.
RECOMMENDED DOSE REDUCTION FOR ADVERSE REACTIONS:
- First Reduction: 30 mg orally once a day for CP-CML, AP-CML, BP-CML, and Ph+ ALL
- Second Reduction: 15 mg orally once a day for CP-CML, AP-CML, BP-CML, and Ph+ ALL
- Third reduction: 10 mg orally once a day for CP-CML and permanently discontinue for AP-CML, BP-CML, and Ph+ ALL patients unable to tolerate the second dose reduction
- Subsequent reduction: Permanently discontinue treatment for CP-CML, AP-CML, BP-CML, and Ph+ ALL
HEPATOTOXICITY:
Elevation of liver transaminase greater than 3 times the upper limit of normal (ULN) and if:
- Occurrence at 45 mg: Interrupt dosing and monitor hepatic function; and resume treatment at 30 mg after recovery to Grade 1 or less (less than 3 x ULN)
- AST or ALT at least 3 times ULN with an elevation of bilirubin greater than 2 times ULN and alkaline phosphatase less than 2 times ULN: Discontinue treatment
ELEVATED LIPASE/PANCREATITIS:
- Serum lipase greater than 1 to 1.5 x ULN: Consider treatment interruption until resolution and then resume at same dose
- Serum lipase greater than 1.5 to 2 times ULN, 2 to 5 times ULN and asymptomatic, or asymptomatic radiologic pancreatitis: Interrupt until Grade 0 or 1 (less than 1.5 times ULN) and then resume at next lower dose
- Serum lipase greater than 2 to 5 times ULN and symptomatic, symptomatic Grade 3 pancreatitis, or serum lipase greater than 5 times ULN and asymptomatic: Interrupt until complete resolution of symptoms and after recovery of lipase elevation Grade 0 or 1, then resume at next lower dose
- Symptomatic pancreatitis and serum lipase greater than 5 times ULN: Discontinue treatment
MYELOSUPPRESSION:
- ANC less than 1 x 10(9)/L or platelets less than 50 x 10(9)/L and if:
- First Occurrence: Interrupt treatment and resume at same dose after recovery to ANC 1.5 x 10(9)/L or greater and platelets 75 x 10(9)/L or greater
- Recurrence: Interrupt treatment until resolution and then resume at next lower dose
ARTERIAL OCCLUSIVE EVENTS:
Cardiovascular or Cerebrovascular:
- Grade 1: Interrupt treatment until resolved, then resume at same dose
- Grade 2: Interrupt treatment until Grade 0 or 1, then resume at next lower dose and discontinue if recurrence
- Grade 3 or 4: Discontinue treatment
Peripheral vascular and other or venous thromboembolic events:
- Grade 1: Interrupt treatment until resolved, resume at same dose
- Grade 2: Interrupt treatment until Grade 0 or 1, then resume at same dose and if recurrence, interrupt treatment until Grade 0 or 1, then resume at next lower dose
- Grade 3: Interrupt treatment until Grade 0 or 1, then resume at next lower dose and discontinue if recurrence
- Grade 4: Discontinue treatment
HEART FAILURE:
- Grade 2 or 3: Interrupt treatment until Grade 0 or 1, then resume at the next lower dose and discontinue if recurrence
- Grade 4: Discontinue treatment
OTHER NON-HEMATOLOGIC ADVERSE REACTIONS:
- Grade 1: Interrupt treatment until resolved, then resume at the same dose
- Grade 2: Interrupt treatment until Grade 0 or 1, then resume at the same dose, and if recurrence, interrupt until Grade 0 or 1, then resume at the next lower dose
- Grade 3 or 4: Interrupt treatment until Grade 0 or 1, then resume at the next lower dose and discontinue if recurrence
Administration Advice:
- This drug may be taken with or without food and at the same approximate time each day.
- Swallow tablets whole; do not crush, break, cut, chew, or dissolve the tablets.
- If a dose is missed, take the next dose at the regularly scheduled time the next day.
- Do not take 2 doses at the same time to make up for a missed dose.
- This drug contains lactose monohydrate, care, and close monitoring is recommended for intolerant patients.
Monitoring:
- Monitor for evidence of arterial occlusive events and venous thromboembolic events.
- Monitor for heart failure.
- Monitor liver function tests at baseline, then at least monthly or as clinically indicated.
- Monitor blood pressure at baseline and as clinically in indicated.
- Monitor serum lipase every 2 weeks for the first 2 months and then monthly thereafter or as clinically indicated.
- Monitor for symptoms of peripheral and cranial neuropathy.
- Monitor for vision at baseline and periodically during treatment.
- Monitor for hemorrhage.
- Monitor for fluid retention.
- Monitor for signs and symptoms of arrhythmias.
- Monitor blood counts every 2 weeks for the first 3 months and then monthly or as indicated for myelosuppression.
Patient Advice:
- Advise the patient to read the approved patient labeling (Medication Guide).
- Advise females of the potential risk to a fetus and inform their healthcare provider of a known or suspected pregnancy.
- Advise females of reproductive potential to use effective contraception during treatment and for at least 3 weeks after the last dose.
- Advise females of the potential for reduced fertility.
- Advise not to breastfeed during treatment and for 6 days after the last dose.
- Advise patients to inform of any planned surgical procedure.
- Advise patients to immediately report any symptoms suggestive of a blood clot such as chest pain, shortness of breath, weakness on one side of the body, speech problems, leg pain, or leg swelling.
- Advise patients to report any signs and symptoms suggestive of hemorrhages such as unusual bleeding or easy bruising.
- Advise patients to report symptoms suggestive of heart complications such as chest pain, shortness of breath, hypertension, palpitations, dizziness, or fainting.
- Advise patients to report any symptoms suggestive of pancreatitides such as nausea, vomiting, abdominal pain, or abdominal discomfort.
- Advise patients to report any developing fluid retention such as leg swelling, abdominal swelling, weight gain, or shortness of breath.
- Advise patients to report fever, infection, headache, seizure, altered mental status, and neurological disturbances.
- Advise patients to report symptoms of liver problems such as jaundice, anorexia, bleeding or bruising.
- Advise patients to avoid drinking grapefruit juice or eating grapefruit during treatment.
- Inform patients that the tablets contain lactose monohydrate.
- Advise patients to report symptoms of neuropathy such as hypo- and hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness.
- Advise patients to report symptoms of ocular toxicity such as blurred vision, dry eye, or eye pain.
Side Effects
The Most Common
- rash
- dry skin
- diarrhea
- constipation
- hair loss
- white patches or sores on the lips or in the mouth and throat
- loss of appetite
- weight loss
- cough
- difficulty falling asleep or staying asleep
- back, bone, joint, limb, or muscle pain
- unusual bruising or bleeding
- bloody or black, tarry stools
- blood in the urine
- bloody vomit
- unusual vaginal bleeding or heavier than usual menstrual bleeding
- vomit that looks like coffee grounds
- frequent nose bleeds
- coughing up blood
- dry, red, painful, or irritated eyes
- sensitivity to light
- blurred vision, floaters, double vision, or other vision changes
- wounds that do not heal
- fever, sore throat, chills, or other signs of infection
- changes in taste; muscle weakness; drooping eyelids or part of face; tingling, burning, pain, or loss of feeling in hands or feet
- headache, seizures, confusion, problems thinking, or changes or loss of vision
- decreased urination
- extreme tiredness or weakness
- weight gain
- swelling of your face, hands, feet, ankles, or lower legs
- pain, swelling, or tenderness in the abdomen (stomach area)
- nausea
- vomiting
- ongoing pain that begins in the stomach area but may spread to the back
More common
- Bladder pain
- bleeding gums
- bloating or swelling of the face, arms, hands, lower legs, or feet
- blurred vision
- chest pain
- chills
- cloudy urine
- confusion
- constipation
- cough or hoarseness
- coughing up blood
- decreased urine output
- difficult, burning, or painful urination
- difficulty with breathing or swallowing
- dilated neck veins
- dizziness
- fainting
- frequent urge to urinate
- increased menstrual flow or vaginal bleeding
- indigestion
- irregular breathing
- joint pain, stiffness, or swelling
- lightheadedness
- lower back, side, or stomach pain
- nervousness
- nosebleeds
- pains in the chest, groin, or legs, especially calves of the legs
- pains in the stomach, side, or abdomen, possibly radiating to the back
- pale skin
- paralysis
- pinpoint red spots on the skin
- pounding in the ears
- prolonged bleeding from cuts
- rapid weight gain
- rapid, shallow breathing
- red or black, tarry stools
- red or dark brown urine
- severe headaches of sudden onset
- slow or fast heartbeat
- sore throat
- sudden loss of coordination
- sudden slurred speech
- sudden vision changes
- tingling of the hands or feet
- ulcers, sores, or white spots in the mouth
- unusual bleeding or bruising
- unusual weight gain or loss
Rare
- Anxiety
- burning, numbness, tingling, or painful sensations
- chest discomfort
- fast, pounding, or irregular heartbeat or pulse
- pain, redness, or swelling in the arms or legs
- unsteadiness or awkwardness
- weakness in the arms, hands, legs, or feet
- Blistering, peeling, loosening of the skin
- bloody, black, or tarry stools
- blue-green halos seen around objects
- clay-colored stools
- dark urine
- decreased appetite
- diarrhea
- dry eyes
- fever
- headache
- heartburn
- indigestion
- itching or skin rash
- joint or muscle pain
- loss of appetite
- nausea and vomiting
- red irritated eyes
- red skin lesions, often with a purple center
- sensitivity of the eyes to light
- sensitivity to heat
- severe vomiting, sometimes with blood
- sore throat
- stomach cramps or tenderness
- sweating
- trouble sleeping
- unusual tiredness or weakness
- vomiting of material that looks like coffee grounds, severe and continuous
- weight loss
- yellow eyes or skin
Drug Interactions
DRUG | INTERACTION |
---|---|
Abaloparatide | The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Ponatinib. |
Abametapir | The serum concentration of Ponatinib can be increased when it is combined with Abametapir. |
Abatacept | The metabolism of Ponatinib can be increased when combined with Abatacept. |
Abciximab | The risk or severity of bleeding can be increased when Abciximab is combined with Ponatinib. |
Abemaciclib | The serum concentration of Abemaciclib can be increased when it is combined with Ponatinib. |
Abiraterone | The metabolism of Ponatinib can be decreased when combined with Abiraterone. |
Acalabrutinib | The metabolism of Ponatinib can be decreased when combined with Acalabrutinib. |
Acebutolol | The metabolism of Ponatinib can be decreased when combined with Acebutolol. |
Acenocoumarol | The risk or severity of bleeding can be increased when Acenocoumarol is combined with Ponatinib. |
Acetaminophen | The metabolism of Ponatinib can be increased when combined with Acetaminophen. |
Acetazolamide | The metabolism of Ponatinib can be decreased when combined with Acetazolamide. |
Acetylsalicylic acid | The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Ponatinib. |
Adalimumab | The metabolism of Ponatinib can be increased when combined with Adalimumab. |
Adenovirus | The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Ponatinib. |
Afatinib | The serum concentration of Afatinib can be increased when it is combined with Ponatinib. |
Albendazole | The metabolism of Ponatinib can be decreased when combined with Albendazole. |
Aldesleukin | The metabolism of Ponatinib can be decreased when combined with Aldesleukin. |
Alectinib | Alectinib may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Ponatinib. |
Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ponatinib. |
Alfentanil | The metabolism of Ponatinib can be decreased when combined with Alfentanil. |
Allogeneic | The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Ponatinib. |
Allopurinol | The risk or severity of adverse effects can be increased when Allopurinol is combined with Ponatinib. |
Almotriptan | The metabolism of Ponatinib can be decreased when combined with Almotriptan. |
Alogliptin | The metabolism of Ponatinib can be decreased when combined with Alogliptin. |
Alpelisib | The serum concentration of Alpelisib can be increased when it is combined with Ponatinib. |
Alprazolam | The metabolism of Ponatinib can be decreased when combined with Alprazolam. |
Alteplase | The risk or severity of bleeding can be increased when Alteplase is combined with Ponatinib. |
Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Ponatinib. |
Ambrisentan | The metabolism of Ponatinib can be decreased when combined with Ambrisentan. |
Aminoglutethimide | The metabolism of Ponatinib can be increased when combined with Aminoglutethimide. |
Aminophenazone | The metabolism of Ponatinib can be decreased when combined with Aminophenazone. |
Amiodarone | The metabolism of Ponatinib can be decreased when combined with Amiodarone. |
Amitriptyline | The metabolism of Ponatinib can be decreased when combined with Amitriptyline. |
Amobarbital | The metabolism of Ponatinib can be increased when combined with Amobarbital. |
Amodiaquine | The metabolism of Ponatinib can be decreased when combined with Amodiaquine. |
Amoxapine | The metabolism of Ponatinib can be decreased when combined with Amoxapine. |
Amphetamine | The metabolism of Ponatinib can be decreased when combined with Amphetamine. |
Amprenavir | The metabolism of Ponatinib can be decreased when combined with Amprenavir. |
Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Ponatinib. |
Anagrelide | The risk or severity of bleeding can be increased when Anagrelide is combined with Ponatinib. |
Anakinra | The metabolism of Ponatinib can be increased when combined with Anakinra. |
Anastrozole | The metabolism of Ponatinib can be decreased when combined with Anastrozole. |
Ancrod | The risk or severity of bleeding can be increased when Ancrod is combined with Ponatinib. |
Anifrolumab | The risk or severity of adverse effects can be increased when Ponatinib is combined with Anifrolumab. |
Anistreplase | The risk or severity of bleeding can be increased when Anistreplase is combined with Ponatinib. |
Anthrax immune | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ponatinib. |
Anthrax vaccine | The risk or severity of infection can be increased when Anthrax vaccine is combined with Ponatinib. |
Antilymphocyte | The risk or severity of adverse effects can be increased when Ponatinib is combined with Antilymphocyte immunoglobulin (horse). |
Antipyrine | The metabolism of Ponatinib can be decreased when combined with Antipyrine. |
Antithrombin Alfa | The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Ponatinib. |
Antithrombin III | The risk or severity of bleeding can be increased when Antithrombin III human is combined with Ponatinib. |
Antithymocyte | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ponatinib. |
Apalutamide | The metabolism of Ponatinib can be increased when combined with Apalutamide. |
Apixaban | The metabolism of Ponatinib can be decreased when combined with Apixaban. |
Apomorphine | The metabolism of Ponatinib can be decreased when combined with Apomorphine. |
Apremilast | The metabolism of Ponatinib can be increased when combined with Apremilast. |
Aprepitant | The metabolism of Ponatinib can be decreased when combined with Aprepitant. |
Ardeparin | The risk or severity of bleeding can be increased when Ardeparin is combined with Ponatinib. |
Arformoterol | The metabolism of Ponatinib can be decreased when combined with Arformoterol. |
Argatroban | The risk or severity of bleeding can be increased when Argatroban is combined with Ponatinib. |
Aripiprazole | The metabolism of Ponatinib can be decreased when combined with Aripiprazole. |
Aripiprazole | The metabolism of Ponatinib can be decreased when combined with Aripiprazole lauroxil. |
Armodafinil | The metabolism of Ponatinib can be increased when combined with Armodafinil. |
Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ponatinib. |
Artemether | The metabolism of Ponatinib can be decreased when combined with Artemether. |
Artenimol | The metabolism of Ponatinib can be decreased when combined with Artenimol. |
Articaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Articaine. |
Asciminib | The serum concentration of Ponatinib can be increased when it is combined with Asciminib. |
Astemizole | The metabolism of Ponatinib can be decreased when combined with Astemizole. |
ACOVID-19 Vacci | The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Ponatinib. |
Asunaprevir | The metabolism of Ponatinib can be decreased when combined with Asunaprevir. |
Atazanavir | The metabolism of Ponatinib can be decreased when combined with Atazanavir. |
Atenolol | The metabolism of Ponatinib can be decreased when combined with Atenolol. |
Atomoxetine | The metabolism of Ponatinib can be decreased when combined with Atomoxetine. |
Atorvastatin | The metabolism of Ponatinib can be decreased when combined with Atorvastatin. |
Avacopan | The metabolism of Ponatinib can be decreased when combined with Avacopan. |
Avanafil | The serum concentration of Avanafil can be increased when it is combined with Ponatinib. |
Avatrombopag | The metabolism of Ponatinib can be increased when combined with Avatrombopag. |
Axitinib | The serum concentration of Axitinib can be increased when it is combined with Ponatinib. |
Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Ponatinib. |
Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Ponatinib. |
Azelastine | The metabolism of Ponatinib can be decreased when combined with Azelastine. |
Azithromycin | The metabolism of Ponatinib can be decreased when combined with Azithromycin. |
Bacillus antigen | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Ponatinib. |
Bacillus | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Ponatinib. |
Bacillus calmette | The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Ponatinib. |
Baricitinib | The risk or severity of adverse effects can be increased when Ponatinib is combined with Baricitinib. |
Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Ponatinib. |
BCG vaccine | The risk or severity of infection can be increased when BCG vaccine is combined with Ponatinib. |
Beclomethasone | The metabolism of Ponatinib can be increased when combined with Beclomethasone dipropionate. |
Belantamab | The serum concentration of Belantamab mafodotin can be increased when it is combined with Ponatinib. |
Belatacept | The risk or severity of adverse effects can be increased when Belatacept is combined with Ponatinib. |
Belimumab | The risk or severity of adverse effects can be increased when Belimumab is combined with Ponatinib. |
Belinostat | The risk or severity of adverse effects can be increased when Belinostat is combined with Ponatinib. |
Belumosudil | The risk or severity of adverse effects can be increased when Ponatinib is combined with Belumosudil. |
Belzutifan | The serum concentration of Ponatinib can be decreased when it is combined with Belzutifan. |
Bemiparin | The risk or severity of bleeding can be increased when Bemiparin is combined with Ponatinib. |
Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Ponatinib. |
Bendroflumethia | The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Ponatinib. |
Benzatropine | The metabolism of Ponatinib can be decreased when combined with Benzatropine. |
Benzocaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Benzocaine. |
Benzthiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Ponatinib. |
Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Benzyl alcohol. |
Bepridil | The metabolism of Ponatinib can be decreased when combined with Bepridil. |
Berotralstat | The serum concentration of Berotralstat can be increased when it is combined with Ponatinib. |
Betamethasone | The metabolism of Ponatinib can be increased when combined with Betamethasone. |
Betamethasone | The metabolism of Ponatinib can be increased when combined with Betamethasone phosphate. |
Betaxolol | The metabolism of Ponatinib can be decreased when combined with Betaxolol. |
Betrixaban | The serum concentration of Betrixaban can be increased when it is combined with Ponatinib. |
Bexarotene | The metabolism of Ponatinib can be increased when combined with Bexarotene. |
Bezafibrate | The metabolism of Ponatinib can be decreased when combined with Bezafibrate. |
Bicalutamide | The metabolism of Ponatinib can be decreased when combined with Bicalutamide. |
Bifonazole | The metabolism of Ponatinib can be decreased when combined with Bifonazole. |
Bimekizumab | The metabolism of Ponatinib can be increased when combined with Bimekizumab. |
Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Ponatinib. |
Biperiden | The metabolism of Ponatinib can be decreased when combined with Biperiden. |
Bisoprolol | The serum concentration of Bisoprolol can be increased when it is combined with Ponatinib. |
Bivalirudin | The risk or severity of bleeding can be increased when Bivalirudin is combined with Ponatinib. |
Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Ponatinib. |
Blinatumomab | The risk or severity of adverse effects can be increased when Ponatinib is combined with Blinatumomab. |
Boceprevir | The metabolism of Ponatinib can be decreased when combined with Boceprevir. |
Bordetella | The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Ponatinib. |
Bortezomib | The serum concentration of Bortezomib can be increased when it is combined with Ponatinib. |
Bosentan | The metabolism of Ponatinib can be increased when combined with Bosentan. |
Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Ponatinib. |
Brentuximab | The serum concentration of Brentuximab vedotin can be increased when it is combined with Ponatinib. |
Brexpiprazole | The metabolism of Ponatinib can be decreased when combined with Brexpiprazole. |
Brigatinib | The metabolism of Brigatinib can be decreased when combined with Ponatinib. |
Brodalumab | The risk or severity of adverse effects can be increased when Ponatinib is combined with Brodalumab. |
Budesonide | The metabolism of Ponatinib can be increased when combined with Budesonide. |
Bupivacaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Bupivacaine. |
Buprenorphine | The metabolism of Ponatinib can be decreased when combined with Buprenorphine. |
Bupropion | The metabolism of Ponatinib can be decreased when combined with Bupropion. |
Buspirone | The metabolism of Ponatinib can be decreased when combined with Buspirone. |
Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with Ponatinib. |
Butacaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Butacaine. |
Butalbital | The metabolism of Ponatinib can be increased when combined with Butalbital. |
Butamben | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Butamben. |
Cabazitaxel | The serum concentration of Cabazitaxel can be increased when it is combined with Ponatinib. |
Cabergoline | The serum concentration of Cabergoline can be increased when it is combined with Ponatinib. |
Cabozantinib | The metabolism of Ponatinib can be decreased when combined with Cabozantinib. |
Caffeine | Caffeine may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Calcitriol | The metabolism of Ponatinib can be increased when combined with Calcitriol. |
Canagliflozin | The serum concentration of Canagliflozin can be increased when it is combined with Ponatinib. |
Canakinumab | The metabolism of Ponatinib can be increased when combined with Canakinumab. |
Candesartan | The metabolism of Ponatinib can be decreased when combined with Candesartan cilexetil. |
Candicidin | The metabolism of Ponatinib can be decreased when combined with Candicidin. |
Cangrelor | The risk or severity of bleeding can be increased when Cangrelor is combined with Ponatinib. |
Cannabidiol | The metabolism of Ponatinib can be decreased when combined with Cannabidiol. |
Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Ponatinib. |
Caplacizumab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Ponatinib. |
Capmatinib | The serum concentration of Ponatinib can be increased when it is combined with Capmatinib. |
Capsaicin | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Capsaicin. |
Carbamazepine | The metabolism of Ponatinib can be increased when combined with Carbamazepine. |
Carbimazole | The therapeutic efficacy of Carbimazole can be decreased when used in combination with Ponatinib. |
Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Ponatinib. |
Carfilzomib | The serum concentration of Carfilzomib can be increased when it is combined with Ponatinib. |
Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Ponatinib. |
Carvedilol | The metabolism of Ponatinib can be decreased when combined with Carvedilol. |
Cefradine | The metabolism of Ponatinib can be increased when combined with Cefradine. |
Celecoxib | The metabolism of Ponatinib can be decreased when combined with Celecoxib. |
Celiprolol | The metabolism of Ponatinib can be decreased when combined with Celiprolol. |
Cenobamate | The serum concentration of Ponatinib can be decreased when it is combined with Cenobamate. |
Cephalexin | The metabolism of Ponatinib can be decreased when combined with Cephalexin. |
Ceritinib | The serum concentration of Ceritinib can be increased when it is combined with Ponatinib. |
Cerivastatin | The metabolism of Ponatinib can be increased when combined with Cerivastatin. |
Certolizumab | The metabolism of Ponatinib can be increased when combined with Certolizumab pegol. |
Cevimeline | The metabolism of Ponatinib can be decreased when combined with Cevimeline. |
Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Ponatinib. |
Chloramphenicol | The metabolism of Ponatinib can be decreased when combined with Chloramphenicol. |
Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Chloroprocaine. |
Chloroquine | The metabolism of Ponatinib can be decreased when combined with Chloroquine. |
Chlorothiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Ponatinib. |
Chlorpheniramine | The metabolism of Ponatinib can be decreased when combined with Chlorpheniramine. |
Chlorpromazine | The metabolism of Ponatinib can be decreased when combined with Chlorpromazine. |
Chlorzoxazone | The metabolism of Ponatinib can be decreased when combined with Chlorzoxazone. |
Cholecalciferol | The metabolism of Ponatinib can be decreased when combined with Cholecalciferol. |
Cholesterol | Cholesterol may increase the excretion rate of Ponatinib which could result in a lower serum level and potentially a reduction in efficacy. |
Ciclesonide | The metabolism of Ponatinib can be decreased when combined with Ciclesonide. |
Cilostazol | The metabolism of Ponatinib can be decreased when combined with Cilostazol. |
Cimetidine | The metabolism of Ponatinib can be decreased when combined with Cimetidine. |
Cinacalcet | The metabolism of Ponatinib can be decreased when combined with Cinacalcet. |
Cinchocaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Cinchocaine. |
Cinnarizine | The metabolism of Ponatinib can be decreased when combined with Cinnarizine. |
Ciprofloxacin | The metabolism of Ponatinib can be decreased when combined with Ciprofloxacin. |
Cisapride | The metabolism of Ponatinib can be decreased when combined with Cisapride. |
Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Ponatinib. |
Citalopram | The metabolism of Ponatinib can be decreased when combined with Citalopram. |
Cladribine | The risk or severity of adverse effects can be increased when Cladribine is combined with Ponatinib. |
Clarithromycin | The metabolism of Ponatinib can be decreased when combined with Clarithromycin. |
Clemastine | The metabolism of Ponatinib can be decreased when combined with Clemastine. |
Clevidipine | The metabolism of Ponatinib can be increased when combined with Clevidipine. |
Clindamycin | The metabolism of Ponatinib can be decreased when combined with Clindamycin. |
Clobazam | The metabolism of Ponatinib can be decreased when combined with Clobazam. |
Clobetasol | The metabolism of Ponatinib can be increased when combined with Clobetasol propionate. |
Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Ponatinib. |
Clofazimine | The metabolism of Ponatinib can be decreased when combined with Clofazimine. |
Clofibrate | The metabolism of Ponatinib can be increased when combined with Clofibrate. |
Clomifene | The serum concentration of Clomifene can be increased when it is combined with Ponatinib. |
Clomipramine | The metabolism of Ponatinib can be decreased when combined with Clomipramine. |
Clonidine | The metabolism of Ponatinib can be decreased when combined with Clonidine. |
Clopidogrel | The metabolism of Ponatinib can be decreased when combined with Clopidogrel. |
Clostridium | The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ponatinib. |
Clozapine | The risk or severity of neutropenia can be increased when Ponatinib is combined with Clozapine. |
Cobicistat | The metabolism of Ponatinib can be decreased when combined with Cobicistat. |
Cobimetinib | The serum concentration of Cobimetinib can be increased when it is combined with Ponatinib. |
Cocaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Cocaine. |
Codeine | The metabolism of Ponatinib can be decreased when combined with Codeine. |
Colchicine | The serum concentration of Colchicine can be increased when it is combined with Ponatinib. |
Conivaptan | The metabolism of Ponatinib can be decreased when combined with Conivaptan. |
Conestrogens | Ponatinib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. |
Copanlisib | The serum concentration of Copanlisib can be increased when it is combined with Ponatinib. |
Corticotropin | The metabolism of Ponatinib can be increased when combined with Corticotropin. |
Cortisone acetate | The metabolism of Ponatinib can be increased when combined with Cortisone acetate. |
Corynebacterium | The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ponatinib. |
Crizotinib | The metabolism of Ponatinib can be decreased when combined with Crizotinib. |
Curcumin | The metabolism of Ponatinib can be decreased when combined with Curcumin. |
Cyanocobalamin | The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Ponatinib. |
Cyclopenthiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Ponatinib. |
Cyclophosphamide | The metabolism of Ponatinib can be increased when combined with Cyclophosphamide. |
Cyclosporine | Ponatinib may increase the immunosuppressive activities of Cyclosporine. |
Cyclothiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Ponatinib. |
Cyproterone | The metabolism of Ponatinib can be decreased when combined with Cyproterone acetate. |
Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Ponatinib. |
Dabigatran | The risk or severity of bleeding can be increased when Dabigatran is combined with Ponatinib. |
Dabigatran | The serum concentration of Dabigatran etexilate can be increased when it is combined with Ponatinib. |
Dabrafenib | The serum concentration of Ponatinib can be decreased when it is combined with Dabrafenib. |
Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ponatinib. |
Daclatasvir | The metabolism of Ponatinib can be decreased when combined with Daclatasvir. |
Dacomitinib | The serum concentration of Dacomitinib can be increased when it is combined with Ponatinib. |
Dactinomycin | The serum concentration of Dactinomycin can be increased when it is combined with Ponatinib. |
Dalfopristin | The metabolism of Ponatinib can be decreased when combined with Dalfopristin. |
Dalteparin | The risk or severity of bleeding can be increased when Dalteparin is combined with Ponatinib. |
Danaparoid | The risk or severity of bleeding can be increased when Danaparoid is combined with Ponatinib. |
Danazol | The metabolism of Ponatinib can be decreased when combined with Danazol. |
Dapagliflozin | The metabolism of Ponatinib can be decreased when combined with Dapagliflozin. |
Dapsone | The metabolism of Ponatinib can be decreased when combined with Dapsone. |
Daptomycin | The serum concentration of Daptomycin can be increased when it is combined with Ponatinib. |
Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ponatinib. |
Darifenacin | The metabolism of Ponatinib can be decreased when combined with Darifenacin. |
Darolutamide | The serum concentration of Ponatinib can be increased when it is combined with Darolutamide. |
Darunavir | The serum concentration of Ponatinib can be increased when it is combined with Darunavir. |
Dasabuvir | The metabolism of Ponatinib can be decreased when combined with Dasabuvir. |
Dasatinib | The serum concentration of Dasatinib can be increased when it is combined with Ponatinib. |
Daunorubicin | The metabolism of Ponatinib can be decreased when combined with Daunorubicin. |
Debrisoquine | The metabolism of Ponatinib can be decreased when combined with Debrisoquine. |
Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Ponatinib. |
Deferasirox | The metabolism of Ponatinib can be increased when combined with Deferasirox. |
Defibrotide | The risk or severity of bleeding can be increased when Defibrotide is combined with Ponatinib. |
Deflazacort | The metabolism of Ponatinib can be increased when combined with Deflazacort. |
Delafloxacin | Ponatinib may decrease the excretion rate of Delafloxacin which could result in a higher serum level. |
Delavirdine | The metabolism of Ponatinib can be decreased when combined with Delavirdine. |
Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Ponatinib. |
Desipramine | The metabolism of Ponatinib can be decreased when combined with Desipramine. |
Desirudin | The risk or severity of bleeding can be increased when Desirudin is combined with Ponatinib. |
Desoximetasone | The risk or severity of adverse effects can be increased when Desoximetasone is combined with Ponatinib. |
Desvenlafaxine | The metabolism of Ponatinib can be decreased when combined with Desvenlafaxine. |
Deucravacitinib | The risk or severity of adverse effects can be increased when Ponatinib is combined with Deucravacitinib. |
Deutetrabenazine | The metabolism of Ponatinib can be decreased when combined with Deutetrabenazine. |
Dexamethasone | The metabolism of Ponatinib can be increased when combined with Dexamethasone. |
Dexamethasone | The metabolism of Ponatinib can be increased when combined with Dexamethasone acetate. |
Dexchlorphenira | The metabolism of Ponatinib can be decreased when combined with Dexchlorpheniramine maleate. |
Dexfenfluramine | The metabolism of Ponatinib can be decreased when combined with Dexfenfluramine. |
Dexibuprofen | The metabolism of Ponatinib can be decreased when combined with Dexibuprofen. |
Dexmedetomidine | The metabolism of Ponatinib can be decreased when combined with Dexmedetomidine. |
Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ponatinib. |
Dextran | The risk or severity of bleeding can be increased when Dextran is combined with Ponatinib. |
Dextroampheta | The metabolism of Ponatinib can be decreased when combined with Dextroamphetamine. |
Dextromethorphan | The metabolism of Ponatinib can be decreased when combined with Dextromethorphan. |
Dextropropox | The metabolism of Ponatinib can be decreased when combined with Dextropropoxyphene. |
Diacerein | The metabolism of Ponatinib can be decreased when combined with Diacerein. |
Diazepam | The metabolism of Ponatinib can be decreased when combined with Diazepam. |
Diclofenac | The metabolism of Ponatinib can be decreased when combined with Diclofenac. |
Dicloxacillin | The metabolism of Ponatinib can be increased when combined with Dicloxacillin. |
Dicoumarol | The risk or severity of bleeding can be increased when Dicoumarol is combined with Ponatinib. |
Diethylstilbestrol | The metabolism of Ponatinib can be decreased when combined with Diethylstilbestrol. |
Difluocortolone | The metabolism of Ponatinib can be increased when combined with Difluocortolone. |
Digitoxin | The serum concentration of Digitoxin can be increased when it is combined with Ponatinib. |
Digoxin | Ponatinib may decrease the excretion rate of Digoxin which could result in a higher serum level. |
Dihydrocodeine | The metabolism of Ponatinib can be decreased when combined with Dihydrocodeine. |
Dihydroergocornine | The metabolism of Ponatinib can be decreased when combined with Dihydroergocornine. |
Dihydroergocristine | The metabolism of Ponatinib can be decreased when combined with Dihydroergocristine. |
Dihydroergotamine | The metabolism of Ponatinib can be decreased when combined with Dihydroergotamine. |
Diltiazem | The metabolism of Ponatinib can be decreased when combined with Diltiazem. |
Dimethyl fumarate | The risk or severity of adverse effects can be increased when Ponatinib is combined with Dimethyl fumarate. |
Dimethyl sulfoxide | The metabolism of Ponatinib can be decreased when combined with Dimethyl sulfoxide. |
Dinutuximab | The risk or severity of adverse effects can be increased when Ponatinib is combined with Dinutuximab. |
Diosmin | The metabolism of Ponatinib can be decreased when combined with Diosmin. |
Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Diphenhydramine. |
Dipyridamole | The risk or severity of bleeding can be increased when Dipyridamole is combined with Ponatinib. |
Diroximel fumarate | The risk or severity of adverse effects can be increased when Ponatinib is combined with Diroximel fumarate. |
Disulfiram | The metabolism of Ponatinib can be decreased when combined with Disulfiram. |
Docetaxel | The metabolism of Ponatinib can be decreased when combined with Docetaxel. |
Dolasetron | The metabolism of Ponatinib can be decreased when combined with Dolasetron. |
Dolutegravir | Ponatinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. |
Domperidone | The metabolism of Ponatinib can be decreased when combined with Domperidone. |
Donepezil | The metabolism of Ponatinib can be decreased when combined with Donepezil. |
Doravirine | The metabolism of Ponatinib can be decreased when combined with Doravirine. |
Dosulepin | The metabolism of Ponatinib can be decreased when combined with Dosulepin. |
Doxazosin | The metabolism of Ponatinib can be decreased when combined with Doxazosin. |
Doxepin | The metabolism of Ponatinib can be decreased when combined with Doxepin. |
Doxorubicin | The serum concentration of Doxorubicin can be increased when it is combined with Ponatinib. |
Dronabinol | The metabolism of Ponatinib can be decreased when combined with Dronabinol. |
Dronedarone | The serum concentration of Ponatinib can be increased when it is combined with Dronedarone. |
Drospirenone | The metabolism of Ponatinib can be decreased when combined with Drospirenone. |
Drotrecogin alfa | The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Ponatinib. |
Duloxetine | The metabolism of Ponatinib can be decreased when combined with Duloxetine. |
Dutasteride | The metabolism of Ponatinib can be decreased when combined with Dutasteride. |
Duvelisib | The metabolism of Ponatinib can be decreased when combined with Duvelisib. |
Dyclonine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Dyclonine. |
Ebastine | The metabolism of Ponatinib can be decreased when combined with Ebastine. |
Ebola Zaire) | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Ponatinib. |
Echinacea | The metabolism of Ponatinib can be increased when combined with Echinacea. |
Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Ponatinib. |
Edetic acid | The risk or severity of bleeding can be increased when Edetic acid is combined with Ponatinib. |
Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Ponatinib. |
Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Ponatinib. |
Efavirenz | The metabolism of Ponatinib can be decreased when combined with Efavirenz. |
Elagolix | The metabolism of Ponatinib can be decreased when combined with Elagolix. |
Elbasvir | The metabolism of Ponatinib can be decreased when combined with Elbasvir. |
Eletriptan | The metabolism of Ponatinib can be decreased when combined with Eletriptan. |
Elexacaftor | The metabolism of Ponatinib can be decreased when combined with Elexacaftor. |
Eliglustat | The metabolism of Ponatinib can be decreased when combined with Eliglustat. |
Eltrombopag | The metabolism of Ponatinib can be decreased when combined with Eltrombopag. |
Elvitegravir | The metabolism of Ponatinib can be decreased when combined with Elvitegravir. |
Emapalumab | The metabolism of Ponatinib can be increased when combined with Emapalumab. |
Enasidenib | The metabolism of Ponatinib can be increased when combined with Enasidenib. |
Encainide | The metabolism of Ponatinib can be decreased when combined with Encainide. |
Encorafenib | The metabolism of Ponatinib can be decreased when combined with Encorafenib. |
Enfortumab | The serum concentration of Enfortumab vedotin can be increased when it is combined with Ponatinib. |
Enoxaparin | The risk or severity of bleeding can be increased when Enoxaparin is combined with Ponatinib. |
Entacapone | The metabolism of Ponatinib can be decreased when combined with Entacapone. |
Enzalutamide | The serum concentration of Ponatinib can be decreased when it is combined with Enzalutamide. |
Epinastine | The metabolism of Ponatinib can be decreased when combined with Epinastine. |
Epinephrine | The metabolism of Ponatinib can be decreased when combined with Epinephrine. |
Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Ponatinib. |
Eplerenone | The metabolism of Ponatinib can be decreased when combined with Eplerenone. |
Epoprostenol | The risk or severity of bleeding can be increased when Epoprostenol is combined with Ponatinib. |
Eptifibatide | The risk or severity of bleeding can be increased when Eptifibatide is combined with Ponatinib. |
Ergotamine | The metabolism of Ponatinib can be decreased when combined with Ergotamine. |
Eribulin | The risk or severity of adverse effects can be increased when Eribulin is combined with Ponatinib. |
Erlotinib | The metabolism of Ponatinib can be decreased when combined with Erlotinib. |
Ertugliflozin | Ponatinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. |
Erythromycin | The metabolism of Ponatinib can be decreased when combined with Erythromycin. |
Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ponatinib. |
Escitalopram | The serum concentration of Ponatinib can be increased when it is combined with Escitalopram. |
Esketamine | The metabolism of Ponatinib can be increased when combined with Esketamine. |
Eslicarbazepine | The metabolism of Ponatinib can be increased when combined with Eslicarbazepine. |
Eslicarbazepine | The metabolism of Ponatinib can be increased when combined with Eslicarbazepine acetate. |
Esmolol | The metabolism of Ponatinib can be decreased when combined with Esmolol. |
Estetrol | The metabolism of Ponatinib can be decreased when combined with Estetrol. |
Estradiol | The metabolism of Ponatinib can be decreased when combined with Estradiol. |
Estradiol acetate | The metabolism of Ponatinib can be increased when combined with Estradiol acetate. |
Estradiol benzoate | The metabolism of Ponatinib can be increased when combined with Estradiol benzoate. |
Estradiol cypionate | The metabolism of Ponatinib can be increased when combined with Estradiol cypionate. |
Estradiol dienant | The metabolism of Ponatinib can be increased when combined with Estradiol dienanthate. |
Estradiol valerate | The metabolism of Ponatinib can be increased when combined with Estradiol valerate. |
Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Ponatinib. |
Eszopiclone | The metabolism of Ponatinib can be decreased when combined with Eszopiclone. |
Etanercept | The metabolism of Ponatinib can be increased when combined with Etanercept. |
Ethambutol | The metabolism of Ponatinib can be decreased when combined with Ethambutol. |
Ethanol | The metabolism of Ponatinib can be increased when combined with Ethanol. |
Ethinylestradiol | The metabolism of Ponatinib can be decreased when combined with Ethinylestradiol. |
Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Ethyl chloride. |
Etidocaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Etidocaine. |
Etoposide | The serum concentration of Etoposide can be increased when it is combined with Ponatinib. |
Etoricoxib | The metabolism of Ponatinib can be decreased when combined with Etoricoxib. |
Etravirine | The metabolism of Ponatinib can be increased when combined with Etravirine. |
Everolimus | The serum concentration of Everolimus can be increased when it is combined with Ponatinib. |
Ezetimibe | Ponatinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. |
Famtozinameran | The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Ponatinib. |
Favipiravir | The metabolism of Ponatinib can be decreased when combined with Favipiravir. |
Febuxostat | The excretion of Ponatinib can be decreased when combined with Febuxostat. |
Fedratinib | The metabolism of Ponatinib can be decreased when combined with Fedratinib. |
Felbamate | The metabolism of Ponatinib can be increased when combined with Felbamate. |
Felodipine | The metabolism of Ponatinib can be decreased when combined with Felodipine. |
Fenfluramine | The metabolism of Ponatinib can be decreased when combined with Fenfluramine. |
Fenofibrate | The metabolism of Ponatinib can be decreased when combined with Fenofibrate. |
Fesoterodine | The metabolism of Ponatinib can be decreased when combined with Fesoterodine. |
Fexinidazole | The metabolism of Ponatinib can be decreased when combined with Fexinidazole. |
Fexofenadine | The serum concentration of Fexofenadine can be increased when it is combined with Ponatinib. |
Filgotinib | The risk or severity of adverse effects can be increased when Ponatinib is combined with Filgotinib. |
Finasteride | The metabolism of Ponatinib can be decreased when combined with Finasteride. |
Finerenone | The metabolism of Ponatinib can be decreased when combined with Finerenone. |
Fingolimod | Ponatinib may increase the immunosuppressive activities of Fingolimod. |
Flecainide | The metabolism of Ponatinib can be decreased when combined with Flecainide. |
Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Ponatinib. |
Flucloxacillin | The metabolism of Ponatinib can be increased when combined with Flucloxacillin. |
Fluconazole | The metabolism of Ponatinib can be decreased when combined with Fluconazole. |
Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Ponatinib. |
Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Ponatinib. |
Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ponatinib. |
Fluindione | The risk or severity of bleeding can be increased when Fluindione is combined with Ponatinib. |
Flunarizine | The metabolism of Ponatinib can be decreased when combined with Flunarizine. |
Flunisolide | The metabolism of Ponatinib can be increased when combined with Flunisolide. |
Fluocinolone | The metabolism of Ponatinib can be increased when combined with Fluocinolone acetonide. |
Fluocinonide | The metabolism of Ponatinib can be increased when combined with Fluocinonide. |
Fluocortolone | The metabolism of Ponatinib can be increased when combined with Fluocortolone. |
Fluorometholone | The risk or severity of adverse effects can be increased when Fluorometholone is combined with Ponatinib. |
Irinotecan | The metabolism of Ponatinib can be decreased when combined with Irinotecan. |
Isavuconazole | The metabolism of Ponatinib can be increased when combined with Isavuconazole. |
Isavuconazonium | The metabolism of Ponatinib can be increased when combined with Isavuconazonium. |
Isoniazid | The metabolism of Ponatinib can be decreased when combined with Isoniazid. |
Isradipine | The metabolism of Ponatinib can be decreased when combined with Isradipine. |
Istradefylline | The metabolism of Ponatinib can be decreased when combined with Istradefylline. |
Itraconazole | The metabolism of Ponatinib can be decreased when combined with Itraconazole. |
Ivacaftor | The metabolism of Ponatinib can be decreased when combined with Ivacaftor. |
Ivermectin | Ponatinib may decrease the excretion rate of Ivermectin which could result in a higher serum level. |
Ivosidenib | The metabolism of Ponatinib can be increased when combined with Ivosidenib. |
Ixabepilone | The risk or severity of adverse effects can be increased when Ixabepilone is combined with Ponatinib. |
Ixekizumab | The risk or severity of adverse effects can be increased when Ponatinib is combined with Ixekizumab. |
Janssen COVID | The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Ponatinib. |
Ja encephalits | The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Ponatinib. |
Ketamine | The metabolism of Ponatinib can be decreased when combined with Ketamine. |
Ketazolam | The metabolism of Ponatinib can be decreased when combined with Ketazolam. |
Ketoconazole | The metabolism of Ponatinib can be decreased when combined with Ketoconazole. |
Ketoprofen | The metabolism of Ponatinib can be decreased when combined with Ketoprofen. |
Ketorolac | The metabolism of Ponatinib can be decreased when combined with Ketorolac. |
Labetalol | The metabolism of Ponatinib can be decreased when combined with Labetalol. |
Lacosamide | The metabolism of Ponatinib can be decreased when combined with Lacosamide. |
Lamivudine | Ponatinib may decrease the excretion rate of Lamivudine which could result in a higher serum level. |
Lanreotide | The metabolism of Ponatinib can be decreased when combined with Lanreotide. |
Lansoprazole | The metabolism of Ponatinib can be decreased when combined with Lansoprazole. |
Lapatinib | The metabolism of Ponatinib can be decreased when combined with Lapatinib. |
Larotrectinib | The serum concentration of Larotrectinib can be increased when it is combined with Ponatinib. |
Lasmiditan | The serum concentration of Ponatinib can be increased when it is combined with Lasmiditan. |
Ledipasvir | The serum concentration of Ledipasvir can be increased when it is combined with Ponatinib. |
Lefamulin | Ponatinib may decrease the excretion rate of Lefamulin which could result in a higher serum level. |
Leflunomide | The risk or severity of adverse effects can be increased when Ponatinib is combined with Leflunomide. |
Lemborexant | The metabolism of Ponatinib can be decreased when combined with Lemborexant. |
Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Ponatinib. |
Lenvatinib | Ponatinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level. |
Lepirudin | The risk or severity of bleeding can be increased when Lepirudin is combined with Ponatinib. |
Lercanidipine | The metabolism of Ponatinib can be decreased when combined with Lercanidipine. |
Lesinurad | The metabolism of Ponatinib can be increased when combined with Lesinurad. |
Letermovir | The metabolism of Ponatinib can be decreased when combined with Letermovir. |
Levamlodipine | The metabolism of Ponatinib can be decreased when combined with Levamlodipine. |
Levobetaxolol | The metabolism of Ponatinib can be decreased when combined with Levobetaxolol. |
Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Levobupivacaine. |
Levoketoconazole | The metabolism of Ponatinib can be decreased when combined with Levoketoconazole. |
Levomilnacipran | The metabolism of Ponatinib can be decreased when combined with Levomilnacipran. |
Levonorgestrel | The metabolism of Ponatinib can be decreased when combined with Levonorgestrel. |
Levothyroxine | The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Ponatinib. |
Lidocaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Lidocaine. |
Linagliptin | The metabolism of Ponatinib can be decreased when combined with Linagliptin. |
Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Ponatinib. |
Linzagolix | The serum concentration of Ponatinib can be increased when it is combined with Linzagolix. |
Liothyronine | The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ponatinib. |
Liotrix | The therapeutic efficacy of Liotrix can be decreased when used in combination with Ponatinib. |
Lipegfilgrastim | Ponatinib may increase the myelosuppressive activities of Lipegfilgrastim. |
Lisdexamfeta | The metabolism of Ponatinib can be decreased when combined with Lisdexamfetamine. |
Lisuride | The metabolism of Ponatinib can be decreased when combined with Lisuride. |
Lofexidine | The metabolism of Ponatinib can be decreased when combined with Lofexidine. |
Lomitapide | The metabolism of Ponatinib can be decreased when combined with Lomitapide. |
Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Ponatinib. |
Lonafarnib | The metabolism of Ponatinib can be decreased when combined with Lonafarnib. |
Loncastuximab | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Ponatinib. |
Loperamide | The excretion of Loperamide can be decreased when combined with Ponatinib. |
Lopinavir | The metabolism of Ponatinib can be decreased when combined with Lopinavir. |
Loratadine | The metabolism of Ponatinib can be decreased when combined with Loratadine. |
Lorcaserin | The metabolism of Ponatinib can be decreased when combined with Lorcaserin. |
Lorlatinib | The metabolism of Ponatinib can be increased when combined with Lorlatinib. |
Lorpiprazole | The metabolism of Ponatinib can be decreased when combined with Lorpiprazole. |
Losartan | The metabolism of Ponatinib can be decreased when combined with Losartan. |
Lovastatin | The metabolism of Ponatinib can be decreased when combined with Lovastatin. |
Lumacaftor | The metabolism of Ponatinib can be increased when combined with Lumacaftor. |
Lumefantrine | The metabolism of Ponatinib can be decreased when combined with Lumefantrine. |
Lusutrombopag | Ponatinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. |
Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Ponatinib. |
Manidipine | The metabolism of Ponatinib can be decreased when combined with Manidipine. |
Mannitol | The serum concentration of Mannitol can be increased when it is combined with Ponatinib. |
Maprotiline | The metabolism of Ponatinib can be decreased when combined with Maprotiline. |
Maribavir | Maribavir may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Mavacamten | The serum concentration of Ponatinib can be decreased when it is combined with Mavacamten. |
Measles virus | The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Ponatinib. |
Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Ponatinib. |
Meclizine | The metabolism of Ponatinib can be decreased when combined with Meclizine. |
Medroxypro | The metabolism of Ponatinib can be increased when combined with Medroxyprogesterone acetate. |
Mefloquine | The serum concentration of Mefloquine can be increased when it is combined with Ponatinib. |
Meloxicam | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Meloxicam. |
Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Ponatinib. |
Meningococcal | The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Ponatinib. |
Meperidine | The metabolism of Ponatinib can be decreased when combined with Meperidine. |
Mephenytoin | The metabolism of Ponatinib can be decreased when combined with Mephenytoin. |
Mepivacaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Mepivacaine. |
Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Ponatinib. |
Meprednisone | The metabolism of Ponatinib can be increased when combined with Meprednisone. |
Mepyramine | The metabolism of Ponatinib can be decreased when combined with Mepyramine. |
Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Ponatinib. |
Mesoridazine | The metabolism of Ponatinib can be decreased when combined with Mesoridazine. |
Mestranol | The metabolism of Ponatinib can be decreased when combined with Mestranol. |
Metamfetamine | The metabolism of Ponatinib can be decreased when combined with Metamfetamine. |
Metamizole | The risk or severity of myelosuppression can be increased when Metamizole is combined with Ponatinib. |
Methadone | The metabolism of Ponatinib can be decreased when combined with Methadone. |
Methimazole | The metabolism of Ponatinib can be decreased when combined with Methimazole. |
Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Ponatinib. |
Methotrimeprazine | The metabolism of Ponatinib can be decreased when combined with Methotrimeprazine. |
Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ponatinib. |
Methoxyflurane | The metabolism of Ponatinib can be decreased when combined with Methoxyflurane. |
Methylene blue | The metabolism of Ponatinib can be decreased when combined with Methylene blue. |
Methylergometrine | The metabolism of Ponatinib can be decreased when combined with Methylergometrine. |
Methylphenobarb | The metabolism of Ponatinib can be increased when combined with Methylphenobarbital. |
Methylprednisolo | The metabolism of Ponatinib can be increased when combined with Methylprednisolone. |
Methylprednisone | The metabolism of Ponatinib can be decreased when combined with Methylprednisone. |
Methysergide | The metabolism of Ponatinib can be decreased when combined with Methysergide. |
Metoclopramide | The metabolism of Ponatinib can be decreased when combined with Metoclopramide. |
Metoprolol | The metabolism of Ponatinib can be decreased when combined with Metoprolol. |
Metreleptin | The metabolism of Ponatinib can be increased when combined with Metreleptin. |
Metronidazole | The metabolism of Ponatinib can be decreased when combined with Metronidazole. |
Metyrapone | The metabolism of Ponatinib can be increased when combined with Metyrapone. |
Mexiletine | The metabolism of Ponatinib can be decreased when combined with Mexiletine. |
Mianserin | The metabolism of Ponatinib can be decreased when combined with Mianserin. |
Miconazole | The metabolism of Ponatinib can be decreased when combined with Miconazole. |
Midazolam | The metabolism of Ponatinib can be decreased when combined with Midazolam. |
Midostaurin | The metabolism of Ponatinib can be decreased when combined with Midostaurin. |
Mifepristone | The serum concentration of Ponatinib can be increased when it is combined with Mifepristone. |
Milnacipran | The metabolism of Ponatinib can be decreased when combined with Milnacipran. |
Minaprine | The metabolism of Ponatinib can be decreased when combined with Minaprine. |
Miocamycin | The metabolism of Ponatinib can be decreased when combined with Miocamycin. |
Mirabegron | The serum concentration of Ponatinib can be increased when it is combined with Mirabegron. |
Mirtazapine | The metabolism of Ponatinib can be decreased when combined with Mirtazapine. |
Mitapivat | The metabolism of Ponatinib can be increased when combined with Mitapivat. |
Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Ponatinib. |
Mitotane | The metabolism of Ponatinib can be increased when combined with Mitotane. |
Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ponatinib. |
Mobocertinib | The serum concentration of Ponatinib can be decreased when it is combined with Mobocertinib. |
Moclobemide | The metabolism of Ponatinib can be decreased when combined with Moclobemide. |
Modafinil | The metabolism of Ponatinib can be increased when combined with Modafinil. |
MCOVID-19 Vac | The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Ponatinib. |
Modified vaccinia | The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Ponatinib. |
Mometasone fur | The metabolism of Ponatinib can be increased when combined with Mometasone furoate. |
Monomethyl fum | The risk or severity of adverse effects can be increased when Ponatinib is combined with Monomethyl fumarate. |
Montelukast | The metabolism of Ponatinib can be decreased when combined with Montelukast. |
Morphine | The metabolism of Ponatinib can be decreased when combined with Morphine. |
Mosunetuzumab | The metabolism of Ponatinib can be decreased when combined with Mosunetuzumab. |
Mumps virus | The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Ponatinib. |
Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Ponatinib. |
Mycophenolate | The metabolism of Ponatinib can be decreased when combined with Mycophenolate mofetil. |
Mycophenolic | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ponatinib. |
Nadolol | The metabolism of Ponatinib can be decreased when combined with Nadolol. |
Nadroparin | The risk or severity of bleeding can be increased when Nadroparin is combined with Ponatinib. |
Nafcillin | The metabolism of Ponatinib can be increased when combined with Nafcillin. |
Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Ponatinib. |
Naloxone | The metabolism of Ponatinib can be decreased when combined with Naloxone. |
Naproxen | The metabolism of Ponatinib can be decreased when combined with Naproxen. |
Natalizumab | The risk or severity of adverse effects can be increased when Ponatinib is combined with Natalizumab. |
Nateglinide | The metabolism of Ponatinib can be decreased when combined with Nateglinide. |
Nebivolol | The metabolism of Ponatinib can be decreased when combined with Nebivolol. |
Nefazodone | The metabolism of Ponatinib can be decreased when combined with Nefazodone. |
Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Ponatinib. |
Nelfinavir | The metabolism of Ponatinib can be decreased when combined with Nelfinavir. |
Netupitant | The metabolism of Ponatinib can be decreased when combined with Netupitant. |
Nevirapine | The metabolism of Ponatinib can be decreased when combined with Nevirapine. |
Niacin | The metabolism of Ponatinib can be decreased when combined with Niacin. |
Nicardipine | The metabolism of Ponatinib can be decreased when combined with Nicardipine. |
Nicergoline | The metabolism of Ponatinib can be decreased when combined with Nicergoline. |
Nifedipine | The metabolism of Ponatinib can be decreased when combined with Nifedipine. |
Nilotinib | The metabolism of Ponatinib can be decreased when combined with Nilotinib. |
Nilutamide | The metabolism of Ponatinib can be decreased when combined with Nilutamide. |
Nilvadipine | The metabolism of Ponatinib can be decreased when combined with Nilvadipine. |
Nimesulide | The risk or severity of bleeding can be increased when Nimesulide is combined with Ponatinib. |
Nintedanib | The metabolism of Ponatinib can be decreased when combined with Nintedanib. |
Nisoldipine | The metabolism of Ponatinib can be decreased when combined with Nisoldipine. |
Nitrendipine | The metabolism of Ponatinib can be decreased when combined with Nitrendipine. |
Nitrofurantoin | Ponatinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
Norethisterone | The metabolism of Ponatinib can be decreased when combined with Norethisterone. |
Norgestimate | The metabolism of Ponatinib can be increased when combined with Norgestimate. |
Nortriptyline | The serum concentration of Nortriptyline can be increased when it is combined with Ponatinib. |
Noscapine | The metabolism of Ponatinib can be decreased when combined with Noscapine. |
Novobiocin | Novobiocin may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Nuvaxovid | The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Ponatinib. |
Obinutuzumab | The risk or severity of adverse effects can be increased when Ponatinib is combined with Obinutuzumab. |
Ocrelizumab | The risk or severity of adverse effects can be increased when Ponatinib is combined with Ocrelizumab. |
Octreotide | The serum concentration of Ponatinib can be increased when it is combined with Octreotide. |
Ofatumumab | The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ponatinib. |
Olanzapine | The metabolism of Ponatinib can be decreased when combined with Olanzapine. |
Olaparib | The metabolism of Ponatinib can be decreased when combined with Olaparib. |
Oliceridine | The metabolism of Ponatinib can be decreased when combined with Oliceridine. |
Olodaterol | The metabolism of Ponatinib can be decreased when combined with Olodaterol. |
Omadacycline | The serum concentration of Omadacycline can be increased when it is combined with Ponatinib. |
Ombitasvir | The metabolism of Ponatinib can be decreased when combined with Ombitasvir. |
Omeprazole | The metabolism of Ponatinib can be increased when combined with Omeprazole. |
Ondansetron | The metabolism of Ponatinib can be decreased when combined with Ondansetron. |
Opium | The metabolism of Ponatinib can be decreased when combined with Opium. |
Oritavancin | The metabolism of Ponatinib can be increased when combined with Oritavancin. |
Orphenadrine | The metabolism of Ponatinib can be decreased when combined with Orphenadrine. |
Osilodrostat | The metabolism of Ponatinib can be decreased when combined with Osilodrostat. |
Osimertinib | The serum concentration of Osimertinib can be increased when it is combined with Ponatinib. |
Ospemifene | The metabolism of Ponatinib can be decreased when combined with Ospemifene. |
Oteseconazole | The serum concentration of Ponatinib can be increased when it is combined with Oteseconazole. |
Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ponatinib. |
Oxamniquine | The metabolism of Ponatinib can be decreased when combined with Oxamniquine. |
Oxcarbazepine | The metabolism of Ponatinib can be increased when combined with Oxcarbazepine. |
Oxetacaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Oxetacaine. |
Oxprenolol | The metabolism of Ponatinib can be decreased when combined with Oxprenolol. |
Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Oxybuprocaine. |
Oxybutynin | The metabolism of Ponatinib can be decreased when combined with Oxybutynin. |
Oxycodone | The metabolism of Ponatinib can be decreased when combined with Oxycodone. |
Oxymorphone | The metabolism of Ponatinib can be decreased when combined with Oxymorphone. |
Ozanimod | Ponatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level. |
Paclitaxel | The metabolism of Ponatinib can be increased when combined with Paclitaxel. |
Pacritinib | The serum concentration of Ponatinib can be increased when it is combined with Pacritinib. |
Palbociclib | The metabolism of Ponatinib can be decreased when combined with Palbociclib. |
Palifermin | The therapeutic efficacy of Palifermin can be decreased when used in combination with Ponatinib. |
Paliperidone | The metabolism of Ponatinib can be decreased when combined with Paliperidone. |
Palonosetron | The metabolism of Ponatinib can be decreased when combined with Palonosetron. |
Panobinostat | The metabolism of Ponatinib can be decreased when combined with Panobinostat. |
Pantoprazole | Pantoprazole may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Paramethadione | The metabolism of Ponatinib can be decreased when combined with Paramethadione. |
Parathyroid | The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ponatinib. |
Paritaprevir | The metabolism of Ponatinib can be decreased when combined with Paritaprevir. |
Parnaparin | The risk or severity of bleeding can be increased when Parnaparin is combined with Ponatinib. |
Paroxetine | The metabolism of Ponatinib can be decreased when combined with Paroxetine. |
Pasireotide | The metabolism of Ponatinib can be decreased when combined with Pasireotide. |
Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Ponatinib. |
Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ponatinib. |
Pegcetacoplan | The risk or severity of adverse effects can be increased when Ponatinib is combined with Pegcetacoplan. |
Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ponatinib. |
Peginterferon | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ponatinib. |
Peginterferon | The metabolism of Ponatinib can be decreased when combined with Peginterferon alfa-2b. |
Peginterferon | The risk or severity of adverse effects can be increased when Ponatinib is combined with Peginterferon beta-1a. |
Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Ponatinib. |
Penbutolol | The metabolism of Ponatinib can be decreased when combined with Penbutolol. |
Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Ponatinib. |
Pentamidine | The metabolism of Ponatinib can be decreased when combined with Pentamidine. |
Pentobarbital | The metabolism of Ponatinib can be increased when combined with Pentobarbital. |
Pentosan polys | The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Ponatinib. |
Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Ponatinib. |
Pentoxifylline | The risk or severity of bleeding can be increased when Pentoxifylline is combined with Ponatinib. |
Perampanel | The metabolism of Ponatinib can be increased when combined with Perampanel. |
Perhexiline | The metabolism of Ponatinib can be decreased when combined with Perhexiline. |
Perphenazine | The metabolism of Ponatinib can be decreased when combined with Perphenazine. |
Pertussis vaccine | The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Ponatinib. |
Pexidartinib | Ponatinib may increase the hepatotoxic activities of Pexidartinib. |
Phenformin | The metabolism of Ponatinib can be decreased when combined with Phenformin. |
Phenindione | The risk or severity of bleeding can be increased when Phenindione is combined with Ponatinib. |
Phenobarbital | The metabolism of Ponatinib can be increased when combined with Phenobarbital. |
Phenol | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Phenol. |
Phenprocoumon | The metabolism of Ponatinib can be decreased when combined with Phenprocoumon. |
Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ponatinib. |
Phenylbutazone | The metabolism of Ponatinib can be increased when combined with Phenylbutazone. |
Phenylbutyric acid | The metabolism of Ponatinib can be decreased when combined with Phenylbutyric acid. |
Phenytoin | The metabolism of Ponatinib can be increased when combined with Phenytoin. |
Pibrentasvir | Ponatinib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level. |
Pimavanserin | The metabolism of Ponatinib can be decreased when combined with Pimavanserin. |
Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ponatinib. |
Pimozide | The metabolism of Ponatinib can be decreased when combined with Pimozide. |
Pindolol | The metabolism of Ponatinib can be decreased when combined with Pindolol. |
Pioglitazone | The metabolism of Ponatinib can be decreased when combined with Pioglitazone. |
Piperaquine | The metabolism of Ponatinib can be decreased when combined with Piperaquine. |
Piperazine | The metabolism of Ponatinib can be decreased when combined with Piperazine. |
Pipotiazine | The metabolism of Ponatinib can be decreased when combined with Pipotiazine. |
Pirfenidone | The metabolism of Ponatinib can be decreased when combined with Pirfenidone. |
Piroxicam | The metabolism of Ponatinib can be decreased when combined with Piroxicam. |
Pitavastatin | The metabolism of Ponatinib can be decreased when combined with Pitavastatin. |
Pitolisant | The serum concentration of Ponatinib can be decreased when it is combined with Pitolisant. |
Polythiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Ponatinib. |
Pomalidomide | The serum concentration of Pomalidomide can be increased when it is combined with Ponatinib. |
Ponesimod | The metabolism of Ponatinib can be decreased when combined with Ponesimod. |
Posaconazole | The metabolism of Ponatinib can be decreased when combined with Posaconazole. |
Potassium Iodide | The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Ponatinib. |
Potassium | The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Ponatinib. |
Practolol | The metabolism of Ponatinib can be decreased when combined with Practolol. |
Pralatrexate | The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ponatinib. |
Pralsetinib | The serum concentration of Pralsetinib can be increased when it is combined with Ponatinib. |
Pramocaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Pramocaine. |
Prasugrel | The risk or severity of bleeding can be increased when Prasugrel is combined with Ponatinib. |
Pravastatin | Pravastatin may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Praziquantel | The metabolism of Ponatinib can be decreased when combined with Praziquantel. |
Prazosin | Ponatinib may decrease the excretion rate of Prazosin which could result in a higher serum level. |
Prednisolone | The metabolism of Ponatinib can be increased when combined with Prednisolone. |
Prednisolone | The metabolism of Ponatinib can be increased when combined with Prednisolone acetate. |
Prednisolone | The metabolism of Ponatinib can be increased when combined with Prednisolone phosphate. |
Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Ponatinib. |
Prednisone | The metabolism of Ponatinib can be increased when combined with Prednisone acetate. |
Pretomanid | The metabolism of Ponatinib can be decreased when combined with Pretomanid. |
Prilocaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Prilocaine. |
Primaquine | The metabolism of Ponatinib can be decreased when combined with Primaquine. |
Primidone | The metabolism of Ponatinib can be increased when combined with Primidone. |
Probenecid | The metabolism of Ponatinib can be increased when combined with Probenecid. |
Procainamide | The metabolism of Ponatinib can be decreased when combined with Procainamide. |
Procaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Procaine. |
Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Ponatinib. |
Prochlorperazine | The metabolism of Ponatinib can be decreased when combined with Prochlorperazine. |
Progesterone | The metabolism of Ponatinib can be decreased when combined with Progesterone. |
Proguanil | The metabolism of Ponatinib can be decreased when combined with Proguanil. |
Promazine | The metabolism of Ponatinib can be decreased when combined with Promazine. |
Promethazine | The metabolism of Ponatinib can be decreased when combined with Promethazine. |
Propafenone | The metabolism of Ponatinib can be decreased when combined with Propafenone. |
Proparacaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Proparacaine. |
Propofol | The metabolism of Ponatinib can be decreased when combined with Propofol. |
Propoxycaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Propoxycaine. |
Propranolol | The metabolism of Ponatinib can be decreased when combined with Propranolol. |
Propylthiouracil | The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Ponatinib. |
Protein C | The risk or severity of bleeding can be increased when Protein C is combined with Ponatinib. |
Protein S | The risk or severity of bleeding can be increased when Protein S human is combined with Ponatinib. |
Protirelin | The therapeutic efficacy of Protirelin can be decreased when used in combination with Ponatinib. |
Prucalopride | The serum concentration of Prucalopride can be increased when it is combined with Ponatinib. |
Pyrimethamine | The metabolism of Ponatinib can be decreased when combined with Pyrimethamine. |
Quetiapine | The metabolism of Ponatinib can be decreased when combined with Quetiapine. |
Quinidine | The serum concentration of Quinidine can be increased when it is combined with Ponatinib. |
Quinine | The metabolism of Ponatinib can be decreased when combined with Quinine. |
Quinupristin | The metabolism of Ponatinib can be decreased when combined with Quinupristin. |
Rabeprazole | Rabeprazole may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Rabies immun | The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Ponatinib. |
Rabies A | The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ponatinib. |
Rabies B | The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Ponatinib. |
Raloxifene | The metabolism of Ponatinib can be decreased when combined with Raloxifene. |
Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Ponatinib. |
Ranitidine | The metabolism of Ponatinib can be decreased when combined with Ranitidine. |
Ranolazine | The serum concentration of Ranolazine can be increased when it is combined with Ponatinib. |
Ravulizumab | The risk or severity of adverse effects can be increased when Ponatinib is combined with Ravulizumab. |
Reboxetine | The metabolism of Ponatinib can be decreased when combined with Reboxetine. |
Regorafenib | The serum concentration of Regorafenib can be increased when it is combined with Ponatinib. |
Relugolix | The serum concentration of Relugolix can be increased when it is combined with Ponatinib. |
Remdesivir | The metabolism of Ponatinib can be decreased when combined with Remdesivir. |
Remoxipride | The metabolism of Ponatinib can be decreased when combined with Remoxipride. |
Repaglinide | The metabolism of Ponatinib can be decreased when combined with Repaglinide. |
Reserpine | The metabolism of Ponatinib can be increased when combined with Reserpine. |
Reteplase | The risk or severity of bleeding can be increased when Reteplase is combined with Ponatinib. |
Revefenacin | The metabolism of Ponatinib can be decreased when combined with Revefenacin. |
Reviparin | The risk or severity of bleeding can be increased when Reviparin is combined with Ponatinib. |
Ribociclib | The metabolism of Ponatinib can be decreased when combined with Ribociclib. |
Rifabutin | The metabolism of Ponatinib can be increased when combined with Rifabutin. |
Rifampicin | The metabolism of Ponatinib can be increased when combined with Rifampicin. |
Rifamycin | The metabolism of Ponatinib can be increased when combined with Rifamycin. |
Rifapentine | The metabolism of Ponatinib can be increased when combined with Rifapentine. |
Rifaximin | The serum concentration of Rifaximin can be increased when it is combined with Ponatinib. |
Rilonacept | The metabolism of Ponatinib can be increased when combined with Rilonacept. |
Rilpivirine | The metabolism of Ponatinib can be decreased when combined with Rilpivirine. |
Riluzole | Ponatinib may decrease the excretion rate of Riluzole which could result in a higher serum level. |
Rimegepant | The serum concentration of Rimegepant can be increased when it is combined with Ponatinib. |
Riociguat | The metabolism of Ponatinib can be decreased when combined with Riociguat. |
Ripretinib | Ponatinib may decrease the excretion rate of Ripretinib which could result in a higher serum level. |
Risankizumab | The risk or severity of adverse effects can be increased when Ponatinib is combined with Risankizumab. |
Risperidone | The metabolism of Ponatinib can be decreased when combined with Risperidone. |
Ritonavir | The metabolism of Ponatinib can be decreased when combined with Ritonavir. |
Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Ponatinib. |
Rivaroxaban | The metabolism of Ponatinib can be decreased when combined with Rivaroxaban. |
Rofecoxib | The metabolism of Ponatinib can be increased when combined with Rofecoxib. |
Roflumilast | Roflumilast may increase the immunosuppressive activities of Ponatinib. |
Rolapitant | The metabolism of Ponatinib can be decreased when combined with Rolapitant. |
Romidepsin | The serum concentration of Romidepsin can be increased when it is combined with Ponatinib. |
Ropeginterfer | The metabolism of Ponatinib can be decreased when combined with Ropeginterferon alfa-2b. |
Ropivacaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Ropivacaine. |
Rosiglitazone | The metabolism of Ponatinib can be decreased when combined with Rosiglitazone. |
Rosuvastatin | The metabolism of Ponatinib can be decreased when combined with Rosuvastatin. |
Rotavirus vaccine | The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Ponatinib. |
Rotigotine | The metabolism of Ponatinib can be decreased when combined with Rotigotine. |
Roxadustat | The serum concentration of Ponatinib can be increased when it is combined with Roxadustat. |
Roxithromycin | The metabolism of Ponatinib can be decreased when combined with Roxithromycin. |
Rubella virus | The risk or severity of infection can be increased when Rubella virus vaccine is combined with Ponatinib. |
Rucaparib | The metabolism of Ponatinib can be decreased when combined with Rucaparib. |
Rufinamide | The metabolism of Ponatinib can be increased when combined with Rufinamide. |
Rupatadine | The metabolism of Ponatinib can be decreased when combined with Rupatadine. |
Ruxolitinib | The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ponatinib. |
Safinamide | Safinamide may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Salmeterol | The metabolism of Ponatinib can be decreased when combined with Salmeterol. |
Salmon calcito | The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Ponatinib. |
Saquinavir | The metabolism of Ponatinib can be decreased when combined with Saquinavir. |
Sarilumab | The metabolism of Ponatinib can be increased when combined with Sarilumab. |
Satralizumab | The serum concentration of Ponatinib can be decreased when it is combined with Satralizumab. |
Saxagliptin | The metabolism of Ponatinib can be decreased when combined with Saxagliptin. |
Secobarbital | The metabolism of Ponatinib can be increased when combined with Secobarbital. |
Secukinumab | The metabolism of Ponatinib can be increased when combined with Secukinumab. |
Selegiline | The metabolism of Ponatinib can be decreased when combined with Selegiline. |
Selexipag | The metabolism of Ponatinib can be decreased when combined with Selexipag. |
Selpercatinib | The serum concentration of Ponatinib can be increased when it is combined with Selpercatinib. |
Selumetinib | The metabolism of Ponatinib can be decreased when combined with Selumetinib. |
Sertindole | The metabolism of Ponatinib can be decreased when combined with Sertindole. |
Sertraline | The metabolism of Ponatinib can be decreased when combined with Sertraline. |
Sildenafil | The metabolism of Ponatinib can be decreased when combined with Sildenafil. |
Silodosin | The excretion of Silodosin can be decreased when combined with Ponatinib. |
Siltuximab | The metabolism of Ponatinib can be increased when combined with Siltuximab. |
Simeprevir | The metabolism of Ponatinib can be decreased when combined with Simeprevir. |
Simvastatin | The metabolism of Ponatinib can be decreased when combined with Simvastatin. |
Siponimod | The risk or severity of adverse effects can be increased when Ponatinib is combined with Siponimod. |
Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ponatinib. |
Sirolimus | The serum concentration of Sirolimus can be increased when it is combined with Ponatinib. |
Sitagliptin | The metabolism of Ponatinib can be decreased when combined with Sitagliptin. |
Sitaxentan | The metabolism of Ponatinib can be decreased when combined with Sitaxentan. |
Smallpox | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Ponatinib. |
Sodium citrate | The risk or severity of bleeding can be increased when Sodium citrate is combined with Ponatinib. |
Sofosbuvir | Ponatinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. |
Solifenacin | The metabolism of Ponatinib can be decreased when combined with Solifenacin. |
Somatostatin | The metabolism of Ponatinib can be decreased when combined with Somatostatin. |
Somatrogon | The metabolism of Ponatinib can be increased when combined with Somatrogon. |
Sorafenib | The metabolism of Ponatinib can be decreased when combined with Sorafenib. |
Sotagliflozin | Sotagliflozin may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Sotalol | The metabolism of Ponatinib can be decreased when combined with Sotalol. |
Sotorasib | The serum concentration of Ponatinib can be decreased when it is combined with Sotorasib. |
Spesolimab | The risk or severity of adverse effects can be increased when Ponatinib is combined with Spesolimab. |
Spironolactone | The metabolism of Ponatinib can be decreased when combined with Spironolactone. |
St. John’s Wort | The metabolism of Ponatinib can be increased when combined with St. John’s Wort. |
Stiripentol | The metabolism of Ponatinib can be decreased when combined with Stiripentol. |
Streptokinase | The risk or severity of bleeding can be increased when Streptokinase is combined with Ponatinib. |
Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Ponatinib. |
Sulfadiazine | The metabolism of Ponatinib can be decreased when combined with Sulfadiazine. |
Sulfamethoxazole | The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ponatinib. |
Sulfaphenazole | The metabolism of Ponatinib can be decreased when combined with Sulfaphenazole. |
Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ponatinib. |
Sulfinpyrazone | The metabolism of Ponatinib can be increased when combined with Sulfinpyrazone. |
Sulodexide | The risk or severity of bleeding can be increased when Sulodexide is combined with Ponatinib. |
Sumatriptan | Ponatinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level. |
Sunitinib | The metabolism of Ponatinib can be decreased when combined with Sunitinib. |
Suvorexant | The metabolism of Ponatinib can be decreased when combined with Suvorexant. |
Tacrolimus | Tacrolimus may increase the immunosuppressive activities of Ponatinib. |
Tadalafil | The metabolism of Ponatinib can be decreased when combined with Tadalafil. |
Tafamidis | The serum concentration of Ponatinib can be increased when it is combined with Tafamidis. |
Tafenoquine | The metabolism of Ponatinib can be decreased when combined with Tafenoquine. |
Talazoparib | The serum concentration of Talazoparib can be increased when it is combined with Ponatinib. |
Tamoxifen | The metabolism of Ponatinib can be increased when combined with Tamoxifen. |
Tamsulosin | The metabolism of Ponatinib can be decreased when combined with Tamsulosin. |
Tasimelteon | The metabolism of Ponatinib can be decreased when combined with Tasimelteon. |
Taurocholic acid | Taurocholic acid may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Tazarotene | The metabolism of Ponatinib can be decreased when combined with Tazarotene. |
Tazemetostat | The metabolism of Ponatinib can be decreased when combined with Tazemetostat. |
Technetium | The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Ponatinib. |
Tecovirimat | The metabolism of Ponatinib can be increased when combined with Tecovirimat. |
Tedizolid | The risk or severity of myelosuppression can be increased when Ponatinib is combined with Tedizolid phosphate. |
Tegafur | The metabolism of Tegafur can be decreased when combined with Ponatinib. |
Tegaserod | The metabolism of Ponatinib can be decreased when combined with Tegaserod. |
Telaprevir | The metabolism of Ponatinib can be decreased when combined with Telaprevir. |
Telithromycin | The metabolism of Ponatinib can be decreased when combined with Telithromycin. |
Telmisartan | Telmisartan may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Telotristat ethyl | The serum concentration of Ponatinib can be decreased when it is combined with Telotristat ethyl. |
Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Ponatinib. |
Temsirolimus | The serum concentration of Temsirolimus can be increased when it is combined with Ponatinib. |
Tenecteplase | The risk or severity of bleeding can be increased when Tenecteplase is combined with Ponatinib. |
Teniposide | The metabolism of Ponatinib can be decreased when combined with Teniposide. |
Tenofovir alafe | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ponatinib. |
Tenofovir | The serum concentration of Tenofovir disoproxil can be increased when it is combined with Ponatinib. |
Tepotinib | The serum concentration of Tepotinib can be increased when it is combined with Ponatinib. |
Teprotumumab | The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ponatinib. |
Terbinafine | The metabolism of Ponatinib can be decreased when combined with Terbinafine. |
Terfenadine | The metabolism of Ponatinib can be decreased when combined with Terfenadine. |
Teriflunomide | The metabolism of Ponatinib can be decreased when combined with Teriflunomide. |
Teriparatide | The therapeutic efficacy of Teriparatide can be decreased when used in combination with Ponatinib. |
Testosterone | The metabolism of Ponatinib can be increased when combined with Testosterone. |
Testosterone | The metabolism of Ponatinib can be decreased when combined with Testosterone cypionate. |
Testosterone | The metabolism of Ponatinib can be decreased when combined with Testosterone enanthate. |
Tetrabenazine | The metabolism of Ponatinib can be decreased when combined with Tetrabenazine. |
Tetracaine | The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Tetracaine. |
Tetracycline | The metabolism of Ponatinib can be decreased when combined with Tetracycline. |
Tezacaftor | The metabolism of Ponatinib can be decreased when combined with Tezacaftor. |
Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Ponatinib. |
Theophylline | The metabolism of Ponatinib can be decreased when combined with Theophylline. |
Thiamylal | The metabolism of Ponatinib can be increased when combined with Thiamylal. |
Thioridazine | The metabolism of Ponatinib can be decreased when combined with Thioridazine. |
Thiotepa | The risk or severity of adverse effects can be increased when Thiotepa is combined with Ponatinib. |
Thyroid, porcine | The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Ponatinib. |
Thyrotropin alfa | The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Ponatinib. |
Ticagrelor | The metabolism of Ponatinib can be decreased when combined with Ticagrelor. |
Tic encephalitis | The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Ponatinib. |
Ticlopidine | The metabolism of Ponatinib can be decreased when combined with Ticlopidine. |
Timolol | The metabolism of Ponatinib can be decreased when combined with Timolol. |
Tinzaparin | The risk or severity of bleeding can be increased when Tinzaparin is combined with Ponatinib. |
Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Ponatinib. |
Tiotropium | The metabolism of Ponatinib can be decreased when combined with Tiotropium. |
Tipranavir | The metabolism of Ponatinib can be decreased when combined with Tipranavir. |
Tirofiban | The risk or severity of bleeding can be increased when Tirofiban is combined with Ponatinib. |
Tivozanib | Tivozanib may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Tixocortol | The risk or severity of adverse effects can be increased when Ponatinib is combined with Tixocortol. |
Tocilizumab | The metabolism of Ponatinib can be increased when combined with Tocilizumab. |
Tofacitinib | Ponatinib may increase the immunosuppressive activities of Tofacitinib. |
Tolbutamide | The metabolism of Ponatinib can be decreased when combined with Tolbutamide. |
Tolterodine | The metabolism of Ponatinib can be decreased when combined with Tolterodine. |
Tolvaptan | The serum concentration of Tolvaptan can be increased when it is combined with Ponatinib. |
Topiramate | The metabolism of Ponatinib can be increased when combined with Topiramate. |
Topotecan | The serum concentration of Topotecan can be increased when it is combined with Ponatinib. |
Torasemide | The metabolism of Ponatinib can be decreased when combined with Torasemide. |
Toremifene | The serum concentration of Toremifene can be increased when it is combined with Ponatinib. |
Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Ponatinib. |
Trabectedin | The metabolism of Ponatinib can be decreased when combined with Trabectedin. |
Tramadol | The metabolism of Ponatinib can be decreased when combined with Tramadol. |
Trametinib | The metabolism of Ponatinib can be decreased when combined with Trametinib. |
Tranylcypromine | The metabolism of Ponatinib can be decreased when combined with Tranylcypromine. |
Trastuzumab | Trastuzumab may increase the neutropenic activities of Ponatinib. |
Trastuzumab | The serum concentration of Trastuzumab emtansine can be increased when it is combined with Ponatinib. |
Trazodone | The metabolism of Ponatinib can be decreased when combined with Trazodone. |
Treprostinil | The metabolism of Ponatinib can be decreased when combined with Treprostinil. |
Tretinoin | The metabolism of Ponatinib can be decreased when combined with Tretinoin. |
Triamcinolone | The metabolism of Ponatinib can be increased when combined with Triamcinolone. |
Triazolam | The metabolism of Ponatinib can be decreased when combined with Triazolam. |
Trichlormethiazide | The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Ponatinib. |
Triclabendazole | The metabolism of Ponatinib can be decreased when combined with Triclabendazole. |
Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Ponatinib. |
Triflusal | The risk or severity of bleeding can be increased when Triflusal is combined with Ponatinib. |
Trilaciclib | Ponatinib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. |
Trilostane | The risk or severity of adverse effects can be increased when Trilostane is combined with Ponatinib. |
Trimethadione | The metabolism of Ponatinib can be decreased when combined with Trimethadione. |
Trimethoprim | The metabolism of Ponatinib can be decreased when combined with Trimethoprim. |
Trimipramine | The serum concentration of Trimipramine can be increased when it is combined with Ponatinib. |
Tripelennamine | The metabolism of Ponatinib can be decreased when combined with Tripelennamine. |
Troglitazone | The metabolism of Ponatinib can be increased when combined with Troglitazone. |
Troleandomycin | The metabolism of Ponatinib can be decreased when combined with Troleandomycin. |
Trospium | The metabolism of Ponatinib can be decreased when combined with Trospium. |
Tucatinib | The metabolism of Tucatinib can be decreased when combined with Ponatinib. |
Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Ponatinib. |
Typhoid Vaccine | The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Ponatinib. |
Typhoid Vi po | The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Ponatinib. |
Ubrogepant | The serum concentration of Ubrogepant can be increased when it is combined with Ponatinib. |
Udenafil | The metabolism of Ponatinib can be decreased when combined with Udenafil. |
Umeclidinium | The metabolism of Ponatinib can be decreased when combined with Umeclidinium. |
Upadacitinib | The risk or severity of adverse effects can be increased when Ponatinib is combined with Upadacitinib. |
Urokinase | The risk or severity of bleeding can be increased when Urokinase is combined with Ponatinib. |
Valbenazine | The metabolism of Ponatinib can be decreased when combined with Valbenazine. |
Valoctocogene | The therapeutic efficacy of Valoctocogene roxaparvovec can be decreased when used in combination with Ponatinib. |
Valproic acid | The metabolism of Ponatinib can be decreased when combined with Valproic acid. |
Vandetanib | Vandetanib may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Vardenafil | The metabolism of Ponatinib can be decreased when combined with Vardenafil. |
Varicella zoster | The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Ponatinib. |
Varicella zoster | The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Ponatinib. |
Vedolizumab | The risk or severity of adverse effects can be increased when Ponatinib is combined with Vedolizumab. |
Velpatasvir | The metabolism of Ponatinib can be decreased when combined with Velpatasvir. |
Vemurafenib | The serum concentration of Vemurafenib can be increased when it is combined with Ponatinib. |
Venetoclax | The serum concentration of Venetoclax can be increased when it is combined with Ponatinib. |
Venlafaxine | The metabolism of Ponatinib can be decreased when combined with Venlafaxine. |
Verapamil | The metabolism of Ponatinib can be decreased when combined with Verapamil. |
Vernakalant | The metabolism of Ponatinib can be decreased when combined with Vernakalant. |
Vibrio cholerae | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Ponatinib. |
Vilanterol | The risk or severity of adverse effects can be increased when Ponatinib is combined with Vilanterol. |
Vilazodone | The metabolism of Ponatinib can be decreased when combined with Vilazodone. |
Viloxazine | The metabolism of Ponatinib can be decreased when combined with Viloxazine. |
Vinblastine | The serum concentration of Vinblastine can be increased when it is combined with Ponatinib. |
Vincristine | The excretion of Vincristine can be decreased when combined with Ponatinib. |
Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Ponatinib. |
Vinflunine | The serum concentration of Vinflunine can be increased when it is combined with Ponatinib. |
Vinorelbine | The metabolism of Ponatinib can be decreased when combined with Vinorelbine. |
Vismodegib | Vismodegib may decrease the excretion rate of Ponatinib which could result in a higher serum level. |
Vitamin E | The metabolism of Ponatinib can be increased when combined with Vitamin E. |
Voclosporin | The risk or severity of adverse effects can be increased when Ponatinib is combined with Voclosporin. |
Vonoprazan | The metabolism of Ponatinib can be decreased when combined with Vonoprazan. |
Vorapaxar | The metabolism of Ponatinib can be decreased when combined with Vorapaxar. |
Voriconazole | The metabolism of Ponatinib can be decreased when combined with Voriconazole. |
Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Ponatinib. |
Vortioxetine | The metabolism of Ponatinib can be decreased when combined with Vortioxetine. |
Voxelotor | The serum concentration of Ponatinib can be increased when it is combined with Voxelotor. |
Voxilaprevir | The metabolism of Ponatinib can be decreased when combined with Voxilaprevir. |
Warfarin | The metabolism of Ponatinib can be increased when combined with Warfarin. |
Ximelagatran | The risk or severity of bleeding can be increased when Ximelagatran is combined with Ponatinib. |
Yellow fever vaccine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Ponatinib. |
Yohimbine | The metabolism of Ponatinib can be decreased when combined with Yohimbine. |
Zafirlukast | The metabolism of Ponatinib can be decreased when combined with Zafirlukast. |
Zaleplon | The metabolism of Ponatinib can be decreased when combined with Zaleplon. |
Zidovudine | The metabolism of Ponatinib can be decreased when combined with Zidovudine. |
Zimelidine | The metabolism of Ponatinib can be decreased when combined with Zimelidine. |
Ziprasidone | The metabolism of Ponatinib can be decreased when combined with Ziprasidone. |
Zolpidem | The metabolism of Ponatinib can be decreased when combined with Zolpidem. |
Zonisamide | The metabolism of Ponatinib can be decreased when combined with Zonisamide. |
Zopiclone | The metabolism of Ponatinib can be decreased when combined with Zopiclone. |
Zuclopenthixol | The metabolism of Ponatinib can be decreased when combined with Zuclopenthixol |
Pregnancy and Lactation
AU TGA pregnancy category D
Pregnancy
Based on its mechanism of action and findings in animals, Iclusig can cause fetal harm when administered to a pregnant woman [see Data]. There are no available data on Iclusig use in pregnant women. In animal reproduction studies, oral administration of ponatinib to pregnant rats during organogenesis caused adverse developmental effects at doses lower than human exposures at the recommended human dose [see Data]. Advise pregnant women of the potential risk to a fetus
Lactation
No information is available on the clinical use of ponatinib during breastfeeding. Because ponatinib is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 24 hours and it might accumulate in the infant. National Comprehensive Cancer Network guidelines recommend avoiding breastfeeding during ponatinib therapy and the manufacturer recommends withholding breastfeeding for 6 days following the last dose.[1]
How should this medicine be used?
Ponatinib comes as a tablet to take by mouth. It is usually taken once a day with or without food. Take ponatinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ponatinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow the tablets whole; do not split, chew, or crush them. Your doctor may need to delay your treatment, adjust your dose, or permanently stop your treatment of ponatinib depending on your response to treatment and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take ponatinib even if you feel well. Do not stop taking ponatinib without talking to your doctor.
What special precautions should I follow?
Before taking ponatinib,
- tell your doctor and pharmacist if you are allergic to ponatinib, any other medications, lactose, or any of the ingredients in ponatinib tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: ketoconazole (Nizoral); medications to reduce stomach acid, such as lansoprazole (Prevacid); and rifampin (Rifadin, Rimactane, in Rifamate, in Rifater). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with ponatinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor if you have or have ever had a bleeding problem; diabetes; pancreatitis (swelling of the pancreas, a gland behind the stomach that produces substances to help with digestion); or if you are lactose intolerant (inability to digest dairy products). Also, tell your doctor if you drink or have ever drunk large amounts of alcohol.
- you should know that ponatinib may decrease fertility in women. However, you should not assume that you or your partner cannot become pregnant. Tell your doctor if you are pregnant or plan to become pregnant. If you are female, you will need to take a pregnancy test before you start treatment. You should use birth control to prevent pregnancy during your treatment with ponatinib and for 3 weeks after you stop taking the medication. Talk to your doctor about the types of birth control that will work for you. If you become pregnant while taking ponatinib, call your doctor immediately. Ponatinib may harm the fetus.
- tell your doctor if you are breastfeeding or plan to breastfeed. You should not breastfeed while taking ponatinib and for 6 days after your final dose.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking ponatinib. If you are scheduled to have surgery, your doctor will tell you to stop taking ponatinib for at least 7 days before the surgery or procedure. Your doctor will tell you when to start taking ponatinib again after your surgery.
- you should know that your blood pressure may increase during your treatment with ponatinib. Your doctor will probably monitor your blood pressure during your treatment.